MINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, announced completion of patient enrollment in the company’s Phase 2, ...

Please provide your email address to receive an email when new articles are posted on . The addition of palbociclib to anti-HER2 and endocrine therapy extended PFS by more than a year. The regimen ...